Exforge

Active Ingredients & Dual Mechanism of Action

1. Amlodipine Besylate (CCB): Inhibits the entry of extracellular calcium ions into vascular smooth muscle and cardiac cells. This promotes direct relaxation and dilation of peripheral blood vessels, reducing total peripheral vascular resistance.
2. Valsartan (ARB): Selectively blocks the binding of angiotensin II to $\text{AT}_1$ receptors in vascular smooth muscle and the adrenal glands. This blocks angiotensin II–mediated vasoconstriction and halts aldosterone release, reducing total fluid retention and vascular tightness.

Dosage Forms & Available Strengths

• Exforge 5 mg / 160 mg: 5 mg Amlodipine + 160 mg Valsartan
• Exforge 10 mg / 160 mg: 10 mg Amlodipine + 160 mg Valsartan
• Exforge 5 mg / 320 mg: 5 mg Amlodipine + 320 mg Valsartan
• Exforge 10 mg / 320 mg: 10 mg Amlodipine + 320 mg Valsartan (maximum recommended strength)

Clinical Indications

• Essential Hypertension: Treatment of high blood pressure in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy alone.
• Initial Therapy: Used as initial treatment in patients likely to require multiple agents to reach their target blood pressure goals.
• Cardiovascular Risk Reduction: Lowering elevated blood pressure to reduce the risk of fatal and non-fatal cardiovascular events, predominantly strokes and myocardial infarctions (heart attacks).

Key Pharmacokinetics

• Absorption: Rapidly absorbed following oral administration. Peak concentration ($C_{max}$) occurs within 2 to 4 hours for valsartan and 6 to 12 hours for amlodipine. Bioavailability is unaffected by food.
• Duration of Action: Sustained 24-hour therapeutic effect supported by amlodipine’s long elimination half-life ($30\text{–}50\text{ hours}$) and valsartan’s receptor affinity.
• Excretion: Valsartan is excreted primarily unchanged via bile/feces; amlodipine is extensively hepatic-metabolized by CYP3A4 and cleared in urine.

Administration Guidelines

• Usage: Administered orally once daily with water, with or without food.
• Administration: Tablets should be swallowed whole; avoid crushing or chewing.
• Dose Titration: Dosage adjustments may be considered after 1 to 2 weeks of continuous therapy.

Safety Profile & Considerations

• Common Side Effects: Peripheral edema (lower leg/ankle swelling), dizziness, headache, fatigue, flushing, and nasopharyngitis.
• Boxed Warning (Fetal Toxicity): Drugs acting on the renin-angiotensin system can cause severe injury or death to the developing fetus. Discontinue Exforge immediately if pregnancy is detected.
• Contraindications: Known hypersensitivity to amlodipine, valsartan, or other dihydropyridines. Do not co-administer with aliskiren in patients with diabetes. Avoid in patients with severe hepatic impairment, biliary obstruction, or severe renal failure.
• Key Drug Interactions:
  • Potassium Supplements / Salt Substitutes: Increases the risk of hyperkalemia (high blood potassium) due to valsartan.
  • Lithium: Concurrent use may lead to increased serum lithium concentration and toxicity.
  • NSAIDs: May reduce blood pressure-lowering effectiveness and increase the risk of severe renal impairment.
  • CYP3A4 Inhibitors/Inducers: Can significantly affect amlodipine blood concentrations.

Note: Exforge is a prescription-only drug. Dose selection, titration, and therapy management must strictly follow the supervision of a licensed healthcare professional.